Anakinra - Swedish Orphan Biovitrum
Alternative Names: 143090-92-0; Antril; Kinaret; Kineret; Recombinant human interleukin-1 receptor antagonist; rhIL-1ra; rIL-1ra; rIL1RNLatest Information Update: 09 Oct 2025
At a glance
- Originator Amgen
- Developer Amgen; CHRU de Tours; Swedish Orphan Biovitrum
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Antigouts; Antineoplastics; Antirheumatics; Recombinant proteins
- Mechanism of Action Interleukin 1 receptor antagonists
-
Orphan Drug Status
Yes - Cryopyrin-associated periodic syndromes; Immunological disorders; Juvenile rheumatoid arthritis
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cryopyrin-associated periodic syndromes; Rheumatoid arthritis
- Registered Adult-onset Still's disease; Autoimmune disorders; COVID-19 pneumonia; Familial Mediterranean fever; Juvenile rheumatoid arthritis
- Phase III COVID 2019 infections
- Phase II Gout; Non-Hodgkin's lymphoma
- Discontinued Ankylosing spondylitis; Graft-versus-host disease; Osteoarthritis; Pneumococcal infections; Septic shock
Most Recent Events
- 11 Apr 2025 Pharmacodynamics data from the phase III SAVE-MORE trial in COVID-2019 pneumonia presented at the 35th Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID-2025)
- 31 Dec 2023 Registered for Cryopyrin-associated periodic syndromes in China (SC) prior to December 2023
- 31 Dec 2023 Registered for Familial Mediterranean fever in China (SC) prior to December 2023